Silexion Therapeutics Corp (SLXN) income statement
SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.15+0.00 (0.00%)
Close on Oct 19, 2026Market cap $28.29KP/E 0.0Yield –
Silexion Therapeutics Corp income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- 1718.9%
Financial strength
- Current ratio
- 1.66
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 129.3%
Valuation
- P/E ratio
- 0.0
- Price to sales
- –
- Price to book
- 0.01
- Dividend yield
- –
See a number that looks wrong?